Understanding the health-related quality of life (HrQoL) of hospitalized COVID-19 survivors is an emerging global challenge arising from the current pandemic. A qualitative study of the experiences of sixteen hospitalized COVID-19 survivors from Nanning City, China, was conducted using semi-structured telephone interviews in May 2020. These first-hand accounts were critically and empirically analysed to identify emerging health and social issues, and provide potential solutions to improve survivors’ quality of life. This in-depth, qualitative study of HrQoL for hospitalized COVID-19 survivors provides the first empirical evidence and conceptual framework with eight dimensions (physical symptoms, anxiety, trauma, economic loss, place-based identity, self-stigma, health self-interventions, and changing lifestyle) for understanding the physiological, psychological, socio-economic and health behavioral aspects of their daily lives. We argue that local and global governments should provide integrated healthcare, social and digital infrastructure to support this vulnerable group. More comparative and multi-disciplinary studies in this area are needed to generate academic standards of assessing health-related quality of life and produce good practice guidelines for promoting urban resilience in response to public health disasters.

Data on the population‐based incidence of cancer‐associated venous thromboembolism (VTE) from racially diverse populations are limited. To evaluate the incidence and burden of cancer‐associated VTE, including demographic and racial subgroups in the general population of Oklahoma County—which closely mirrors the United States. A population‐based prospective study. We conducted surveillance of VTE at tertiary care facilities and outpatient clinics in Oklahoma County, Oklahoma, from 2012–2014. Surveillance included reviewing all imaging reports used to diagnose VTE and identifying VTE events from hospital discharge data and death certificates. Cancer status was determined by linkage to the Oklahoma Central Cancer Registry. We used Poisson regression to calculate crude and age‐adjusted incidence rates of cancer‐associated VTE per 100 000 general population per year, with 95% confidence intervals (95% CI). The age‐adjusted incidence (95% CI) of cancer‐associated VTE among adults age ≥ 18 was 70.0 (65.1–75.3). The age‐adjusted incidence rates (95% CI) were 85.9 (72.7–101.6) for non‐Hispanic Blacks, 79.5 (13.2–86.5) for non‐Hispanic Whites, 18.8 (8.9–39.4) for Native Americans, 15.6 (7.0–34.8) for Asian/Pacific Islanders, and 15.2 (9.2–25.1) for Hispanics. Recurrent VTE up to 2 years after the initial diagnosis occurred in 38 of 304 patients (12.5%) with active cancer and in 34 of 424 patients (8.0%) with a history of cancer > 6 months previously. Age‐adjusted incidence rates of cancer‐associated VTE vary substantially by race and ethnicity. The relatively high incidence rates of first VTE and of recurrence warrant further assessment of strategies to prevent VTE among cancer patients.